Retatrutide and Trazodone: Interaction Evidence Record

At a glance

• Review question / Is there FDA-reviewed or study-specific interaction evidence for retatrutide and Trazodone?
• Best evidence / registry searches and trial reports
• Evidence snapshot / 2026-08-09
• Commercial status / no FDA-approved product or ordinary retail supply
• HealthRX role / independent educational review; no retatrutide product or treatment offer

Direct answer

The answer is limited. Trazodone is a medicine, procedure, food, or drink named in the research question. The specifically named pharmacokinetic records in the 2026-08-09 snapshot involved midazolam, warfarin, caffeine, and metoprolol—not Trazodone. Absence of a dedicated named record is an evidence gap; it is not proof of compatibility or incompatibility.

The wording here is deliberately evidence-specific. “A study exists,” “a registry lists a site,” and “a paper reports an endpoint” are different statements from “a product is approved,” “a treatment works,” or “a person should use it.” This page makes only the first type of statement and links the controlling source.

Evidence map for Trazodone interaction evidence

How HealthRX evaluated this question

Interaction evidence has levels. A named pharmacokinetic study can measure exposure under controlled conditions; a clinical outcomes study can examine events in a defined population; an FDA label can synthesize reviewed evidence into instructions. Background use, anecdotes, and mechanism-based reasoning sit below those sources and should not be presented as settled guidance.

For this page, HealthRX asked: (1) Is trazodone interaction evidence named in the protocol or publication? (2) Was it a prespecified endpoint, eligibility factor, subgroup, or only background context? (3) Is the record complete, current, and peer reviewed? (4) Does an FDA action or approved label exist? That sequence prevents a research observation from being rewritten as a product claim.

Evidence checks specific to this record

Subgroup stability

A subgroup result needs adequate representation, a prespecified interaction test, transparent multiplicity handling, and consistency across relevant analyses. Merely listing a demographic or clinical subgroup does not establish a subgroup-specific conclusion about trazodone interaction evidence.

Terminology discipline

Keep 'investigational,' 'registered,' 'completed,' 'published,' 'expanded access,' and 'FDA-approved' distinct. For trazodone interaction evidence, these terms describe different stages or pathways and should never be collapsed into the idea that a commercial treatment is available.

Eligibility versus evidence

Eligibility criteria define who could enter a study; they do not prove that each eligible group was adequately enrolled or separately analyzed. A careful review of trazodone interaction evidence distinguishes permitted enrollment from actual representation and prespecified analysis.

Source version

ClinicalTrials.gov records can change as recruitment, locations, outcomes, and completion dates are updated. Record the review date for trazodone interaction evidence, inspect the change history, and let the current primary record control over an older search snippet or copied summary.

Multiplicity control

When many doses, time points, subgroups, or outcomes are examined, chance findings become more likely. A review of trazodone interaction evidence should identify which analyses were prespecified and how the statistical plan addressed multiple testing before treating a signal as durable evidence.

What remains unresolved

Retatrutide has no FDA-approved prescribing information or FDA-reviewed interaction table. Mechanism-based guesses, class analogies, anecdotes, and use of Trazodone as background therapy cannot establish whether concurrent use is safe, unsafe, beneficial, or appropriate.

The source hierarchy also matters. An FDA action controls approval status. ClinicalTrials.gov controls the public registry record. A peer-reviewed report can describe study methods and observations. A press release, seller page, social post, search result, or anecdote cannot replace those sources.

What evidence could change the answer

The strongest future evidence would be a registered study naming Trazodone, prespecifying pharmacokinetic or clinical endpoints, documenting exposure and timing, and publishing complete results.

Any new result should be read with its protocol and statistical analysis plan. Important checks include enrollment, prespecified outcomes, follow-up duration, missing-data handling, multiplicity, participant flow, sponsor involvement, and whether the finding has undergone peer review and regulatory review.

Current federal and commercial status

Retatrutide remains investigational. No retatrutide product is FDA-approved for any indication or available through ordinary commercial prescription or retail sale. FDA states that retatrutide cannot be used in compounding under federal law. HealthRX does not offer it. FDA's current statement says retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. A ClinicalTrials.gov study or eligibility-limited expanded-access record is not commercial approval, ordinary prescribing, retail availability, or evidence that HealthRX offers the investigational substance.

Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.

Source selection and review method

HealthRX reviewed primary or primary-index sources current to 2026-08-09: ClinicalTrials.gov pharmacokinetic record NCT05445232; Rosenstock et al., phase 2 type 2 diabetes trial report; Jastreboff et al., phase 2 obesity trial report; FDA status statement for unapproved GLP-1 drugs; 21 CFR 312.7, Promotion of investigational drugs. Sources were selected because they control regulatory status, register a study, or index a peer-reviewed clinical report. The review reports study design and evidence limits without reproducing promotional outcome claims or converting protocols into patient instructions.

Frequently asked questions

›Is there an FDA-reviewed interaction table for Trazodone?

No. Retatrutide has no FDA-approved prescribing information and therefore no FDA-reviewed public interaction table.

›Does no dedicated study mean there is no interaction?

No. Absence of a named study is an evidence gap, not proof that concurrent use is compatible or incompatible.

›What source would answer the question best?

A registered study that names the substance, prespecifies pharmacokinetic or clinical endpoints, and publishes complete results would be more informative. FDA-reviewed labeling would be needed for public-use instructions.

References

1. ClinicalTrials.gov. Retatrutide pharmacokinetic interaction-study record. 2026. https://clinicaltrials.gov/study/NCT05445232
2. Rosenstock J, Frias J, Jastreboff AM, et al. Phase 2 retatrutide type 2 diabetes trial report. The Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37385280/
3. Jastreboff AM, Kaplan LM, Frias JP, et al. Phase 2 retatrutide obesity trial report. New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
4. U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
5. Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7